MedTrace Logo

Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis

NCT07154381 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2025-09-04

No results posted yet for this study

Summary

Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).

Conditions

  • Cardiac Amyloidosis

Sponsors & Collaborators

  • University Hospital, Essen

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-09
Primary Completion
2025-10-31
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07154381 on ClinicalTrials.gov